Recurrence After Complete Resection for Non-Small Cell Lung Cancer in the National Lung Screening Trial

Potter, Alexandra L.; Costantino, Christina L.; Suliman, Raiya A.; Haridas, Chinmay; Senthil, Priyanka; Kumar, Arvind; Mayne, Nicholas R.; Panda, Nikhil; Martin, Linda W.; Yang, Chi‐Fu Jeffrey

doi:10.1016/j.athoracsur.2023.06.004

Cited by 12 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 1,2 ] Surgery is the main treatment for NSCLC, however, patients with locally advanced NSCLC still face a high risk of recurrence and metastasis after surgery. [ 3,4 ] Therefore, exploring the potential molecular targets that affect the progression of NSCLC may provide new biomarkers for the treatment of NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Exosomal circ_0000735 contributes to non‐small lung cancer malignant progression

Liu,

Wu,

Wang

et al. 2024

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Circular RNA is an important regulator for non‐small cell lung cancer (NSCLC). Circ_0000735 has been found to be significantly overexpressed in NSCLC tissues. Therefore, its role and mechanism in NSCLC progression need to be further explored. The expression levels of circ_0000735, miR‐345‐5p and A disintegrin and metalloprotease 19 (ADAM19) were determined using quantitative real‐time PCR. EdU staining, wound healing and transwell assays were utilized to detect cell proliferation and metastasis. The protein levels of metastasis markers, exosome markers and ADAM19 were determined using western blot. Animal experiments were performed to confirm the role of circ_0000735 in NSCLC tumorigenesis. The exosomes from cells and serum were identified using transmission electron microscopy and nanoparticle tracking analysis. We found that circ_0000735 was upregulated in NSCLC, and its knockdown repressed NSCLC cell proliferation and metastasis. In terms of mechanism, circ_0000735 targeted miR‐345‐5p to regulate ADAM19. MiR‐345‐5p inhibitor reversed the suppressive effect of circ_0000735 knockdown on NSCLC progression, and ADAM19 overexpression abolished the inhibition effect of miR‐345‐5p on NSCLC progression. Also, animal experiments showed that silencing of circ_0000735 reduced NSCLC tumorigenesis. In addition, exosomes mediated the intercellular transmission of circ_0000735, and serum exosomal circ_0000735 might be an important indicator for the diagnosis of NSCLC. In conclusion, circ_0000735 facilitated NSCLC progression via miR‐345‐5p/ADAM19 pathway, and serum exosomal circ_0000735 might be a potential biomarker for NSCLC diagnosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Exosomal circ_0000735 contributes to non‐small lung cancer malignant progression

Liu,

Wu,

Wang

et al. 2024

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“… 2 Surgical resection is the preferred treatment for early stage lung cancer; however, about 20%–55% of lung cancer patients relapse after surgery. 3 Unfortunately, most lung cancer patients are already at an advanced stage upon diagnosis, and the 5‐year overall survival rate is usually less than 20%. 4 At present, it has been established that lung cancer is mainly caused by the interaction of environmental and genetic factors, but the specific molecular mechanism is still being studied.…”

Section: Introductionmentioning

confidence: 99%

Regulatory mechanism and expression level of PRPS2 in lung cancer

Meng,

Zhang,

et al. 2024

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundLung cancer, with high morbidity and mortality, is the commonest respiratory system neoplasm, which seriously endangers the life safety of patients. In this study, the effect of PRPS2 on cell progression was preliminarily investigated.MethodsImmunohistochemical staining, western blot and reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) were performed to verify the expression level of PRPS2 in lung cancer. Lung cancer cell lines with stable downregulation of PRPS2 were constructed in A549 cells and NCIH460 cells. The function of PRPS2 silencing on the proliferation ability was verified by the EdU and cell colony formation experiment. Scratch and transwell tests were conducted to verify the role of PRPS2 silencing on the migratory and invasive ability of cells. The impact of PRPS2 silencing on cell apoptosis and cell cycle was verified by flow cytometry test. The effects of PRPS2 silencing on apoptosis‐associated proteins were assessed by western blot assay. The function of PRPS2 silencing on tumor growth in vivo was studied through xenograft tumor experiment.ResultsIn comparison with normal tissues, PRPS2 was upregulated in lung cancer tissues. PRPS2 knockdown notably hindered the migratory ability, invasive ability and proliferation, but accelerated cell apoptosis. In vivo experiments confirmed that PRPS2 silencing blocked the growth of transplanted tumors.ConclusionIn lung cancer, PRPS2 silencing suppressed the malignant progression, indicating that PRPS2 might be a novel biomarker for lung cancer treatment and diagnosis.

show abstract

“…However, not all of these early-stage cancers were overdiagnosed. Notably, participants with completely resected stage IA lung cancer in the National Lung Screening Trial had a 5-year cumulative incidence of recurrence of 16%, and 81% of the recurrences were distant metastases [ 7 ]. As a tumour size of >1 cm is a significant predictive factor of growth in non-solid lung nodules [ 8 ], we hypothesised that adenocarcinoma in situ (AIS), bronchioloalveolar carcinoma (BAC) and minimally invasive adenocarcinoma (MIA) with tumour sizes >1 cm are unlikely to be overdiagnosed.…”

mentioning

confidence: 99%

Possible overdiagnosis of early-stage lung adenocarcinoma among never-smokers in Taiwan

Yang,

Lai,

et al. 2024

ERJ Open Res

View full text Add to dashboard Cite

Extract Overdiagnosis in cancer screening denotes the detection of cancer that does not cause premature mortality [1, 2]. A standard approach to estimate the magnitude of overdiagnosis is through randomised controlled trials and comparing the cancer incidence in the screened group with that in the control group [3]. Recent studies from Asian countries showed that the promotion of computed tomography (CT) screening among individuals who mostly never smoked was associated with a rapidly increased incidence of early-stage lung cancer, whereas a corresponding declined incidence of advanced lung cancer was not observed [4–6]. However, not all of these early-stage cancers were overdiagnosed. Notably, participants with completely resected stage IA lung cancer in the National Lung Screening Trial had a 5-year cumulative incidence of recurrence of 16%, and 81% of the recurrences were distant metastases [7]. As a tumour size of >1 cm is a significant predictive factor of growth in non-solid lung nodules [8], we hypothesised that adenocarcinoma in situ (AIS), bronchioloalveolar carcinoma (BAC) and minimally invasive adenocarcinoma (MIA) with tumour sizes >1 cm are unlikely to be overdiagnosed. We attempted to corroborate our hypothesis by comparing the survival of never-smoking patients with that of matched referents.

show abstract

Recurrence After Complete Resection for Non-Small Cell Lung Cancer in the National Lung Screening Trial

Cited by 12 publications

References 22 publications

Exosomal circ_0000735 contributes to non‐small lung cancer malignant progression

Exosomal circ_0000735 contributes to non‐small lung cancer malignant progression

Regulatory mechanism and expression level of PRPS2 in lung cancer

Possible overdiagnosis of early-stage lung adenocarcinoma among never-smokers in Taiwan

Contact Info

Product

Resources

About